Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency

Hafid Mezdour, Guilhem Larigauderie, Graciela Castro, Gerard Torpier, Jamila Fruchart, Maxime Nowak, Jean-Charles Fruchart, Mustapha Rouis, and Nobuyo Maeda

Laboratoire de Génétique Expérimentale and Institut National de la Santé et de la Recherche Médicale U-545, Institut Pasteur de Lille, 59019 Lille, France; and Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7525

Abstract  Human data raised the possibility that coronary heart disease is associated with mutations in the apolipoprotein gene cluster APOA1/C3/A4 that result in multideficiency of cluster-encoded apolipoproteins and hypoalphalipoproteinemia. To test this hypothesis, we generated a mouse model for human apolipoprotein A-I (apoA-I)/C-III/A-IV deficiency. Homozygous mutants (Apoa1/c3/a4<sup>−/−</sup>) lacking the three cluster-encoded apolipoproteins were viable and fertile. In addition, feeding behavior and growth were apparently normal. Total cholesterol (TC), high density lipoprotein cholesterol (HDLc), and triglyceride levels in the plasma of fasted mutants fed a regular chow were 32% (P < 0.001), 17% (P < 0.001), and 70% (P < 0.01), respectively, those of wild-type mice. When fed a high-fat Western-type (HFW) diet, Apoa1/c3/a4<sup>−/−</sup> mice showed a further decrease in HDLc concentration and a moderate increase in TC, essentially in non-HDL fraction. The capacity of Apoa1/c3/a4<sup>−/−</sup> plasma to promote cholesterol efflux in vitro was decreased to 75% (P < 0.001), and LCAT activity was decreased by 38% (P < 0.01). Despite the very low total plasma cholesterol, the imbalance in lipoprotein distribution caused small but detectable aortic lesions in one-third of Apoa1/c3/a4<sup>−/−</sup> mice fed a HFW diet. In contrast, none of the wild-type mice had lesions.

These results demonstrate that Apoa1/c3/a4<sup>−/−</sup> mice display clinical features similar to human apoA1/C-III/A-IV deficiency (i.e., marked hypoalphalipoproteinemia) and provide further support for the apoa1/c3/a4 gene cluster as a minor susceptibility locus for atherosclerosis in mice.—Mezdour, H., G. Larigauderie, G. Castro, G. Torpier, J. Fruchart, M. Nowak, J.-C. Fruchart, M. Rouis, and N. Maeda. Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency. J. Lipid Res. 2006. 47: 912-920.

Supplementary key words  apoa1/c3/a4 gene cluster (mouse) • APOA1/C3/A4 gene cluster (human) • knockout mouse • hypoalphalipoproteinemia • high-fat Western-type diet • atherosclerosis

A strong inverse association exists between plasma high density lipoprotein cholesterol (HDLc) levels and the incidence of coronary artery disease in humans (1). The major locus controlling HDLc levels is APOA1 (for apolipoprotein A-I), a member of the apolipoprotein gene cluster APOA1/C3/A4 (2). The cluster genes, APOA1, APOC3, and APOA4, are evolutionarily related and tandemly organized in a region of 17 kb DNA on human chromosome 11, proximal to APOA5, a new member of the apolipoprotein gene family (3). These APOA1/C3/A4 genes code for three apolipoproteins, apoA-I, apoC-III, and apoA-IV, respectively. ApoA-I is a 28 kDa protein synthesized in the liver and small intestine (4). It is the major protein component of HDL. Through its ability to promote cholesterol efflux from cultured cells (5) and to activate LCAT (6), apoA-I plays a key role in reverse cholesterol transport, a mechanism postulated to prevent extrahepatic tissues from accumulating excess cholesterol (7). Apolipoprotein C-III is a 9 kDa protein produced predominantly in the liver. It is a major component of plasma chylomicrons and VLDL. ApoC-III inhibits the hydrolysis of triglyceride by lipoprotein lipase. Apolipoprotein A-IV is a 46 kDa protein associated primarily with chylomicrons and HDL and is present in the lipoprotein-free fraction of plasma (8). It is involved in dietary fat absorption and likely in reverse cholesterol transport (9, 10).

The contribution of the APOA1/C3/A4 gene cluster to coronary heart disease has been recognized for nearly two decades. Strong support came from rare human patients with apoA1/C-III or apoA1/C-III/A-IV deficiencies (11, 12). These patients had very low HDL concentrations in plasma and suffered from premature atherosclerosis. Also, an association of a high risk for premature atherosclero-

Abbreviations: APOA1/C3/A4, apolipoprotein gene cluster (human); apoa1/c3/a4, apolipoprotein gene cluster (mouse); Apoa1/c3/a4<sup>−/−</sup> and Apoa1/c3/a4<sup>−/−</sup>, gene cluster wild-type (+/+ or AαAα+/+) and knockout (−/− or AαAα−/−) mice, respectively; HDLC, high density lipoprotein cholesterol; HFW, high-fat Western-type; IDL, intermediate density lipoprotein; SR-BI, scavenger receptor class B type I; TC, total cholesterol.

†To whom correspondence should be addressed.
e-mail: hafid mezdour@pasteur-lille.fr

912  Journal of Lipid Research  Volume 47, 2006
This is an Open Access article under the CC BY license.
sis and lower plasma levels of apoA-I has been observed; however, few mutations in the APOA1/C3/A4 gene cluster that result in reduced levels or absence of apoA-I lead to atherosclerosis (13). In contrast, single deficiencies in apoA-I, apoC-III, and likely apoA-IV are not sufficient to predispose mice to atherosclerosis (14–16), whereas overexpression of human apoA-I (17) and apoA-IV (18) but not apoC-III (19) had been reported to protect mice from genetic or diet-induced atherosclerosis. In addition, simultaneous expression of apoA-I/C-III/A-IV in mice induced marked hypertriglyceridemia and the accumulation of potentially atherogenic lipoproteins but decreased susceptibility to atherosclerosis in an Apoe’/’ genetic background (20). Together, these observations suggested a complex role of the apoa1/c3/a4 gene cluster, as an integrated unit, in plasma lipoprotein metabolism and atherosclerosis.

To begin to explore this issue, we generated a mouse model for human apoA-I/C-III/A-IV deficiency by gene targeting. In homozygous mutants, absence of apoA-I, apoC-III, and apoA-IV from plasma was accompanied by severe hypoalphalipoproteinemia and mild hypotriglyceridemia. In vitro analysis showed a reduced capacity of plasma to promote cholesterol efflux and LCAT activity. However, homozygous mutants displayed a limited susceptibility to atherosclerosis.

**METHODS**

**Generation of apoA-I/C-III/A-IV-deficient mice**

Mouse genomic DNA used for targeting vector was cloned from a 129/Ola genomic library. The targeting construct contains a 6 kb EcoRI-SacI fragment 5’ to the apoa1 gene as 5’ homology and a 3 kb BamHI-HindIII fragment 3’ of the apoa4 gene as 3’ homology. Neomycin phosphotransferase and thymidine kinase genes were used for positive/negative selection. A subclone (BK4) of the mouse strain 129/Ola embryonic stem cell line, E14TG2a, was cultured and electroporated with the targeting construct, as described previously (21). The embryonic stem cells surviving the positive/negative selection were analyzed by Southern blot after EcoRI digestion and hybridization to a 1 kb probe from apoa4 intron 2. Targeted clones that carry a 15 kb deletion of the apoa1/C3/a4 gene cluster (Apoa1/c3/a4 allele) were identified by the presence of a 4.8 kb EcoRI fragment, compared with a 15 kb wild-type fragment. Targeted embryonic stem cells were microinjected into C57BL/6 blastocysts, and resulting chimeraic mice were mated with C57BL/6 mice to generate F1 heterozygous mutants. Homozygous mutants were F2 generation animals derived from mating F1 Apoa1/c3/a4 allele mice. Tail DNA was digested with EcoRI, and Southern blots were hybridized with the mouse and Southern blots were hybridized with the mouse apoA1 probe to identify mice carrying the targeted allele. F2 generation mice with a 129/Ola×C57BL/6 mixed genetic background were used for characterization and experiments. Mice (8–10 weeks old) were matched for age and gender, and wild-type littermates were used as controls. Mice were housed in a temperature-controlled room with alternating 12 h light (7 AM–7 PM) and dark periods. The animals had access to diet and water ad libitum. All procedures involving animal handling and care were followed in accordance with institutional guidelines.

**Northern blot and real-time RT-PCR analysis**

Total RNAs were extracted from tissues (liver and small intestine) with RNeasy (Qiagen), purified, and electrophoresed (20 µg total RNA/lane) on 1% agarose gels containing formaldehyde (22). Samples were blotted onto Hybond-N membranes (Amersham Pharmacia Biotech, Saclay, France) and hybridized with 32P-labeled cDNA-specific probes. For quantitative PCR, reverse-transcribed apoA1 and apoE cDNA was quantified by real-time PCR on a MX 4000 apparatus (Stratagene) using specific oligonucleotide primers for apoa1 (5’-CTC GCC CCC ACA AAC TCA CAC G-3’ and 5’-AGG TAG GTG TCA TGC CGA AAA G-3’) and specific primers for apoa4 (5’-GGG AAG GTG TAA TCC GTC TCC ACA G-3’ and 5’-CAT GCT CAA CAT CTC CCC CTT CTC C-3’) to normalize the assay. The forward primer used for mouse apoE was 5’-CCG TGG TCT TGG TCA TGC TGA CAG GAT-3’, and the reverse primer was 5’-GTT CTT GTG TCA CTT GGG AGC TCT GCA GCT-3’. Therefore, the final values reported here were obtained from these standards, with coefficient factors determined after addition to controls. HDLc levels were determined in plasma after precipitation of apoB-containing lipoproteins with dextran sulfate-Mg2+ (23). TC and HDLc were first determined using homemade standards constituted of pools of mouse plasma. Nevertheless, these standards underestimated both HDL and TC concentrations. Therefore, the final values reported here were obtained after correction with coefficient factors determined after additional calibrations of our initial standards with a commercial standard (Roche). For gel filtration analysis with fast-protein liquid chromatography (Amersham Pharmacia Biotech), equal volumes of plasma samples from the indicated genotypes were pooled, 200 µl was fractionated using two serially linked Superose 6 HR and Superose 12 HR columns, and TC was determined in 100 µl of each collected fraction using an enzymatic method (Sigma).

**Analysis of plasma metabolic activity**

Rat Fu5AH hepatoma cells, which have a high expression level of scavenger receptor class B type 1 (SR-BI), and J774 mouse...
macrophages, which express ABCA1 and SR-BI at very low levels, were used to assess cholesterol efflux, as described previously (24), except that J774 cells were not pretreated with cAMP, a molecule that upregulates ABCA1 gene expression. [3H]cholesterol-loaded cells were incubated for 3 h with 2.5% diluted plasma. All efflux values are reported as averages of at least three determinations in different wells. Isolated human HDL samples were included in each assay as positive controls. LCAT activity was determined using the exogenous proteoliposome substrate method with 25 µl of plasma from female mice (25). Experiments were repeated twice with three different pools of samples for controls and mutants (coefficient of variation <5%).

Histological analysis

Mice were euthanized, and the hearts were perfused from the apex with a cold Krebs-Ringer buffer and fixed in a fixative containing 4% paraformaldehyde in PBS, pH 7.4. The hearts, containing the aortic origin, and other tissues (liver, lung, etc.) were carefully removed and fixed in paraformaldehyde overnight. Serial cryosections were obtained from tissues and stained using Oil Red O and hematoxylin (25).

Statistical analysis

Results are expressed as means ± SD. In all experiments, non-transgenic littersmates of each line were used as controls. Statistical differences in apolipoprotein and lipid levels between different groups of animals were evaluated using Student's two-tailed t-test, unless indicated otherwise. Group differences or correlations with P < 0.05 were considered statistically significant.

RESULTS

ApoA-I/C-III/A-IV-deficient mouse

To ensure total ablation of the apoa1/c3/a4 gene cluster, a gene-targeting vector was constructed such that homologous recombination would delete 13 kb of the mouse’s endogenous cluster, including the three apoa1 coding exons, the entire apoc3 gene, intergenic regions, and the first two exons of apoa4 (Fig. 1A, B). Loss of expression of the cluster genes was demonstrated by Northern blot analysis of total liver and intestine mRNA (Fig. 1C), and the absence of apoaI, apoc-III, and apoa-IV proteins from plasma was demonstrated by Western blot analysis using specific anti-mouse apolipoprotein antisera (Fig. 2B). Therefore, we consider the Apoa1/c3/a4−/− a functional null. Animals homozygous for the ablated cluster genes appeared healthy and have apparently normal growth and feeding behavior.

ApoA-I/C-III/A-IV deficiency causes dyslipidemia

On chow diet, total plasma TC and HDLc concentrations were lower than those of wild-type littermates by 68% and 83%, respectively. Their triglyceride concentration was lower by 29% compared with normal controls, but the decrease was statistically significant only in females (Table 1). The mean ratio of TC to HDLc was 2.6 in Apoa1/c3/a4−/− versus 1.4 in Apoa1/c3/a4+/+, reflecting a severe reduction of HDLc. Severe hypoalphalipoproteinemia was also demonstrated by agarose gel electrophoresis showing reduced α fraction of lipoproteins (Fig. 2A). Plasma lipid levels did not change significantly with age or gender (data not shown).

Plasma samples from several mice of each apoa1/c3/a4 genotype were pooled and applied to the Superose 6 and 12 columns to fractionate the lipoproteins by size (Fig. 3A). In wild-type mice fed regular chow diet, the major lipoprotein eluted in the region corresponding to HDL. Only a small amount of cholesterol was found in regions corresponding to VLDL, intermediate density lipoprotein (IDL), and LDL. Both male and female homozygous mutants had similar lipoprotein profiles, which demonstrates a dramatically reduced amount of cholesterol in the HDL fraction (Fig. 3A).

![Fig. 1. Targeted disruption of the mouse apolipoprotein gene cluster apoa1/c3/a4. A: Schematic representation of the gene-targeting strategy. a: The mouse apoa1/c3/a4 gene cluster (wild-type allele). b: Targeting construct containing genes for neomycin phosphotransferase (neo) and herpes simplex virus thymidine kinase (TK) used for selection, and 5' and 3' regions of homology. c: The resulting targeted allele. The sizes of diagnostic fragments are shown between the EcoRI sites. B: BamHI; H, HindIII; R, EcoRI; S, SacI. B: Southern blot analysis of tail DNA digested with EcoRI and hybridized with the mouse apoa probe to identify F2 generation mice carrying the targeted allele. The 15 kb hybridizing EcoRI fragment indicates the wild-type allele, and the 4.8 kb fragment indicates the mutated allele. C: Northern blot analysis. Total RNA from liver and intestine of each genotype was subjected to electrophoresis, and expression of the cluster genes was examined using specific cDNA probes for mouse apoa1, apoc3, and apoa4. Mouse β-actin was used as the loading control.](image-url)
ApoA-I/C-III/A-IV-deficient mice

Response to the high-fat diet

When fed a HFW diet for 16 weeks, wild-type and homozygous mutant animals responded differently (Table 2). In Apoa1/c3/a4−/− males and females, TC increased by 52% and 39%, whereas HDLc decreased by 7- and 2.5-fold, respectively. In Apoa1/c3/a4+/− males and females, TC increased by 72% and 50%, with increases in HDLc of 19% and 9%, respectively. The TC/HDLc ratio increased to 8.6 in Apoa1/c3/a4−/− males and females, suggesting a further imbalance of plasma cholesterol distribution in Apoa1/c3/a4−/− mice. In contrast, plasma triglyceride levels were less affected by the high-fat diet in either normal or mutant animals.

A 16 week high-fat diet resulted in an increase in the lipoprotein fractions eluting in the VLDL/IDL region and a further decrease in the HDL fraction in Apoa1/c3/a4−/− mice (Fig. 3B). The increase in TC, therefore, was mainly the result of increased VLDL/IDL cholesterol, as confirmed by the increase in the preβ fraction of lipoproteins on agarose gel electrophoresis (Fig. 2A). Mice tolerated high fat without obvious distress.

Impaired plasma metabolic activity

In the Fu5AH cell model, plasma from Apoa1/c3/a4−/− mice promoted cholesterol efflux, a pathway that involves SR-BI, 4-fold less efficiently than Apoa1/c3/a4+/− mouse plasma (4.1 ± 1.2% vs. 16.3 ± 3.4% in males and 7.1 ± 2.6% vs. 15.4 ± 2.2% in females; P < 0.001 and 0.01, respectively) (Fig. 4A). In the J774 macrophage model, the capacity of Apoa1/c3/a4−/− plasma for cholesterol efflux, which is mediated mostly through ABCA1 and to a less extent by SR-BI, was 65% that of wild-type plasma (6.3 ± 0.8% vs. 9.6 ± 1.1% in males and 6.5 ± 1.1% vs. 9.2 ± 0.9% in females; P < 0.01) (Fig. 4B). Similarly, up to a 45% decrease in LCAT activity was observed in Apoa1/c3/a4−/− mice compared with Apoa1/c3/a4+/+ mice (11.2 ± 2.2% vs. 18.1 ± 1.7% in males and 8.9 ± 2.3% vs. 19.9 ± 1.8% in females; P < 0.01) (Fig. 4C).

Histology

No atherosclerotic lesions were observed in Apoa1/c3/a4−/− mice maintained on regular chow (n = 8), even in two homozygotes older than 10 months of age. In contrast, small atherosclerotic lesions were present in the aortas of 4 males out of 10 and 1 female out of 5 Apoa1/c3/a4−/− mice fed a HFW diet for 16 weeks. These lesions were limited to fatty streaks with small populations of foam cells near the aortic valve attachment sites (Fig. 5A, B). No lesion was observed in wild-type controls fed the same high-fat diet (n = 15). A complete necropsy of Apoa1/c3/a4−/− and Apoa1/c3/a4+/+ mice was performed to determine other morphologic changes secondary to ablation of the apoA1/c3/a4 gene cluster. No gross histopathological differences from normal animals were found in tissues of Apoa1/c3/a4−/− animals fed a chow diet, such as the lung.

TABLE 1. Concentration of plasma lipids in mice fed a normal chow diet

| Genotype   | Gender | TC       | HDLc     | Triglycerides | TC/HDLc |
|------------|--------|----------|----------|---------------|---------|
| Apoa1/c3/a4+/+ | Male   | 69.3 ± 11.9 (9) | 56.3 ± 15.2 (8) | 53.5 ± 9.2 (5) | 1.2     |
|            | Female | 82.5 ± 21.5 (4) | 51.0 ± 8.5 (2)  | 68.8 ± 17.7 (4) | 1.6     |
| Apoa1/c3/a4−/− | Male   | 24.4 ± 6.0* (9) | 8.8 ± 2.3* (8)  | 45.8 ± 8.6 (9)  | 2.8     |
|            | Female | 23.4 ± 7.7* (5) | 9.4 ± 3.3* (5)  | 37.6 ± 4.2* (5) | 2.4     |

HDLc, high density lipoprotein cholesterol; TC, total cholesterol. Data are means ± SD. Numbers of mice are indicated in parentheses.

*P < 0.001, Apoa1/c3/a4−/− versus Apoa1/c3/a4+/+ matched for gender.

**P < 0.01, Apoa1/c3/a4−/− versus Apoa1/c3/a4+/+ matched for gender.
kidney, spleen, and liver (Fig. 5C, D). Feeding a high-fat diet to wild-type mice for a long period caused severe fatty changes in their livers (Fig. 5E). Thus, wild-type livers were enlarged and pale. The hepatocytes in the wild-type livers were enlarged with microvesicular lipid deposits. In contrast, ApoA1/c3/a4<sup>2/-2</sup> mice fed the same diet have relatively normal livers. Histologically, the ApoA1/c3/a4<sup>2/-2</sup> liver had very few lipid-laden cells (presumably Kupffer cells) in the sinusoidal spaces surrounding hepatocytes, with essentially normal appearance (Fig. 5D). In marked contrast, most of the ApoA1/c3/a4<sup>2/-2</sup> male and female mutants had enlarged spleens, and severe splenomegaly was observed in 4 out of 15 mice (3 males and 1 female) fed a HFW diet (Fig. 5F).

**DISCUSSION**

In this study, we investigated the role of the apoa1/c3/a4 gene cluster in plasma lipoprotein metabolism in mouse. Like humans with apoA-I/C-III/A-IV deficiency, the ApoA1/c3/a4<sup>2/-2</sup> mutants showed severe hypoalphalipoproteinemia, mild hypotriglyceridemia, and an apparent decrease in non-HDL particles corresponding to ß- and preß fractions of lipoproteins (Fig. 2A). In contrast to cluster-deficient patients, however, combined deficiencies of apoA-I, apoC-III, and apoA-IV did not predispose mice to severe atherosclerosis. It is well established that mice are naturally resistant to spontaneous atherosclerosis. The most susceptible strain is C57BL/6, which develops fatty lesions only when fed a high-fat diet (15% fat, 1.5% cholesterol, with 0.5% cholate) (25). In this study, ApoA1/c3/a4<sup>2/-2</sup> mice were fed a less toxic and more physiological “Western-type” diet containing 21% fat and 0.2% cholesterol without cholate. This diet is not atherogenic in wild-type mice even in a susceptible C57BL/6 strain, although it accelerates lesion formation in genetically predisposed mice such as LDL receptor-deficient mice and apoE-deficient mice (26). Interestingly, despite having only 30 mg/dl total plasma cholesterol, one-third of ApoA1/c3/a4<sup>2/-2</sup> mice fed a HFW diet developed small but detectable aortic lesions. Although this heterogeneity may be attributable to their genetic background (F2 between C57BL/6 and 129/Ola), this suggests that the increased TC/HDLc ratio contributes to the atherosclerosis in ApoA1/c3/a4<sup>2/-2</sup> mice. Although additional studies are clearly necessary, these observations suggest a possible contribution of the apoa1/c3/a4 gene cluster to atheroprotection.

When fed a HFW diet, plasma cholesterol levels in ApoA1/c3/a4<sup>2/-2</sup> mice were less affected than in ApoA1/c3/a4<sup>1/-1</sup> normal controls. Although cholesterol levels in normal male and female mice increased by 72% and 50%, respectively, mostly in VLDL, IDL, and LDL fractions and less so in HDL, these levels increased in ApoA1/c3/a4<sup>2/-2</sup> mice by only 52% and 39%, respectively, exclusively in the VLDL/LDL range of lipoproteins. One possible explanation for the smaller increase in non-HDLc in the mutants fed a HFW diet is that mice lacking apoA-I/C-III/A-IV could have a poorer absorption of fat compared with nor-
nary heart disease is believed to reside in its ability to pro-
protein synthesis.
lipoproteins and/or abnormal lipid absorption and lipo-
suggests either a faster catabolism of apoC-III-deficient
olism in the non-HDL fraction of lipoproteins, which
are expressed as means
in triplicate according to an exogenous substrate method. Values
experiments with triplicate wells. C: LCAT activity was determined
determined by the Mann-Whitney nonparametric test.
Apoa1/c3/a4
(11). Thus, despite apparently normal feeding behavior
apoA-I/C-III deficiencies have normal lipid absorption
fatty acids was observed (12). In contrast, patients with
III/A-IV deficiency, in whom an abnormal absorption of
during fat absorption (27) and in patients with apoA-I/C-
observation that the secretion of apoA-IV is increased
IV in the intestinal absorption of fat comes from the
mal mice. Support for the possible involvement of apoA-
IV in the intestinal absorption of fat comes from the observation that the secretion of apo-AIV is increased
during fat absorption (27) and in patients with apoA-I/C-
III/A-IV deficiency, in whom an abnormal absorption of
fatty acids was observed (12). In contrast, patients with
apoA-I/C-III deficiencies have normal lipid absorption
(11). Thus, despite apparently normal feeding behavior
and growth, ApoA1/c3/a4−/− mice have a defective metabo-
olism in the non-HDL fraction of lipoproteins, which
suggests either a faster catabolism of apoC-III-deficient
lipoproteins and/or abnormal lipid absorption and lipop-
proteins.

The protective mechanism of HDL with respect to coro-
nary heart disease is believed to reside in its ability to pro-
mote cholesterol efflux from peripheral tissues, a key
process in reverse cholesterol transport, a mechanism pos-
tulated to prevent extrahepatic tissues from accumulating
excess cholesterol (7, 28). Efflux of cholesterol occurs via
multiple mechanisms: aqueous diffusion, SR-BI, or ABCA1.
Both diffusion-mediated and SR-BI-mediated efflux occur
to phospholipid-containing acceptors. In both cases, the
flux of cholesterol is bidirectional, with the direction of
net flux depending on the cholesterol gradient. In con-
trast, efflux via ABCA1 is unidirectional and mediates the
cellular efflux of phospholipids and cholesterol to
lipid-poor apolipoproteins. The ABCA1-mediated process
plays a significant role in the formation of nascent HDLs
and facilitates the removal of additional excess cellular
cholesterol, which is esterified by LCAT. The relative im-
portance of the SR-BI and ABCA1 efflux pathways in
preventing the development of atherosclerotic plaque is
not known but will depend on the expression levels of
the two proteins and on the type of cholesterol acceptors
available. A number of apolipoproteins have been impli-
cated in the process of promoting the efflux of free cho-
lesterol from the macrophages, including apoA-I, apoA-IV,
and apoE. Cholesterol efflux is significantly impaired in
cluster knockout mice but had only a limited effect on
atherosclerosis susceptibility. These results suggest that,
in addition to apoA-I/C-III/A-IV deficiency, a further
imbalance in lipoprotein distribution (i.e., an increase in
atherogenic lipoprotein level) is the primary factor af-
flecting cholesterol homeostasis in peripheral tissues
leading to foam cell formation. One can also speculate
that a limitation in atherosclerosis susceptibility in ApoA1/
c3/a4−/− mice could be related to apoE. It is well known
that lipid transport in mice is highly dependent on apoE
(26, 29), a protein that is produced by various tissues (30).
There were no alterations in the apoE levels in ApoA1/c3/
a4−/− mice compared with wild-type mice (data not
shown). It was observed that macrophage-derived apoE
exerts antiatherogenic properties largely independent of
its concentration in plasma and effects on plasma lipop-
proteins, likely through its contribution to cholesterol
efflux from macrophages. Indeed, transplantation of wild-
type bone marrow or the selective expression of a human
apoE transgene in macrophages decreased atherosclerosis
in apoE-deficient mice (31). Therefore, decreased choles-
terol influx caused low total and LDL-cholesterol, and an
efficient apoE-mediated cholesterol efflux may limit
atherogenesis in apoA-I/C-III/A-IV deficiency.

Other known genetic determinants associated with apoA-I
deficiency and hypoalphalipoproteinemia are Lcat and
Abca1 (1, 32). Indeed, like ApoA1/c3/a4−/− and ApoA1−/−
mice, Lcat−/− and Abca1−/− mice display marked decreases
in plasma levels of TC (∼70%) and HDLc (∼80–90%) in
homozygous mutants (33–35), but a decrease in triglyc-
ride level was observed only in apoC-III deficiency, secondary
to apoc3 gene deletion in ApoA1/c3/a4−/− mice or down-
expression in ApoA1−/− mice (Table 3). Downexpression of
apoc3, but not apoa5, results from interference by the near-
by neomycin resistance cassette (14, 21). In contrast, apoa5
gene expression was found to be normal in ApoA1/c3/a4−/−

---

Fig. 4. Plasma metabolic activities. A, B: Plasma capacity to induce
acellular cholesterol efflux was determined using Fu5Ah hepa-
toma cells (A) and J774 cells (B). A 2.5% dilution of plasma from
Apoa1/c3/a4−/− controls (open bars) and Apoa1/c3/a4−/− mutants
(hatched bars) fed a HFW diet for 16 weeks was incubated for 3 h
with [14C]cholesterol-labeled cells. Data are from representative
experiments with triplicate wells. C: LCAT activity was determined
in triplicate according to an exogenous substrate method. Values
are expressed as means ± SD. **p < 0.001, ***p < 0.01 as deter-
mined by the Mann-Whitney nonparametric test.
mice (data not shown) and so likely in \( \text{Apoa}^{1/-} \) mutants, consistent with transgenic studies showing that the apoC-III enhancer regulates the expression of apoA-I, apoC-III, and apoA-IV but not apoA-V in vivo (36). These data demonstrate that \( \text{Apoa}^{1/-} \) mice are apoA-I/C-III-deficient and differ from \( \text{Apoa}^{1/c3/a4/-} \) mice mostly by the presence of apoA-IV. However, like \( \text{Abea}^{1/-} \) and \( \text{Leai}^{1/-} \) mice, \( \text{Apoa}^{1/-} \) mutants displayed susceptibility to atherosclerosis only in severe hypercholesterolemia (i.e., in the \( \text{Apoe}^{2/-} \) or \( \text{Ldlr}^{2/-} \) background) (37–39), whereas \( \text{Apoa}^{1/c3/a4/-} \) mutants developed small atherosclerotic lesions in less atherogenic conditions. These results suggest that, despite a minor contribution to plasma HDLc variation, apoA-IV may play a significant role in atheroprotection. Further comparative studies of these hypoalphalipoproteinemia models (i.e., \( \text{Apoa}^{1/c3/a4/-} \) mice vs. \( \text{Apoa}^{1/-} \) mice) will likely provide better insight into the specific roles of apoA-IV in lipid metabolism and atherosclerosis.

HDL particles have been shown to protect LDL from oxidative modification (40, 41), to suppress adhesion molecular expression, and to induce cyclooxygenase-2 in vascular endothelium (42), properties that are believed to be protective against atherosclerosis. The lower level of HDL and the absence of apoA-I and apoA-IV-containing particles in \( \text{Apoa}^{1/c3/a4/-} \) mice fed a HFW diet may increase the oxidative modifications of apoB-containing lipoproteins and the physiological dysfunctions of vascular endothelium. Moreover, these modified particles could be cleared through extrahepatic tissues. Thus, it is interesting that morphological examination of mice at necropsy revealed protection from fatty changes of hepatocytes but enlarged spleens in \( \text{Apoa}^{1/c3/a4/-} \) mice. Prolonged exposure to a high-fat diet increased the occurrence of splenomegaly, an abnormality that was also reported in patients with Tangier disease (32) and in ABCA1-deficient mice (34), although not yet in human apoA-I/C-III/A-IV deficiency. Although the mechanism leading to splenomegaly-associated hypoalphalipoproteinemia has not been identified, one hypothesis involves a dysfunction in cholesterol efflux from macrophages.

### Table 3. Phenotypes of mouse models for hypoalphalipoproteinemia

| Genotype | ApoA-I | ApoC-III | ApoA-IV | TC | HDLc | Triglycerides | Aortic Lesions | Ref. |
|----------|--------|----------|---------|----|------|---------------|---------------|-----|
| \( \text{Apoa}^{1/c3/a4/-} \) | 0      | 0        | 0       | 32%| 17%  | 70%           | HFW diet: ±  | (14, 21, 37) |
| \( \text{Apoa}^{1/-} \)      | 0      | ↓        | n.r.    | 33%| 20%  | 45%           | HFC diet: \( \text{Ldlr}^{-/-} \): + | (33, 38)   |
| \( \text{Leai}^{1/-} \)      | ↓      | n.r.    | n.r.    | ≤30%| ≤7%  | ≤100%         | \( \text{Ldlr}^{-/-} \) or \( \text{Apoe}^{-/-} \): + | (34, 35, 39) |
| \( \text{Abca}^{1/-} \)      | ↓      | n.r.    | n.r.    | ≤30%| ≤5%  | ≤100%         | \( \text{Ldlr}^{-/-} \) or \( \text{Apoe}^{-/-} \): \( \text{Abca}^{1/-/BM} \): + | (34, 35, 39) |

ApoA-I, apolipoprotein A-I. Values shown are relative concentrations (percentage of wild-type controls); arrows indicate effects on plasma apolipoproteins. Lesion formation was determined in mutants with the indicated genetic background, in bone marrow transplantation in the \( \text{Apoe}^{2/-} \) background (\( \text{Abca}^{1/-/BM} \)), or in diet-induced hypercholesterolemia (HFC, high-fat and high-cholesterol diet containing cholate). n.r., not reported; +, increased susceptibility; ±, low susceptibility; =, no effect on susceptibility.
In summary, our findings demonstrate that ApoA-I/C3/A4/A5− mice display marked hypoalphalipoproteinemia and that apoA-I/C-III/A-IV deficiency has a profound impact on plasma lipoprotein metabolism. However, in contrast to humans, our results in mice suggest that hypoalphalipoproteinemia secondary to apoA-I/C-III/A-IV deficiency requires additional genetic or environmental risk factors that increase LDL-cholesterol level for the initiation of atherosclerosis.  

The authors thank Kimberly Khuckman, Joelle Warein, Laurent Pouilly, Isabelle Riva, Catherine Lasselin, Corinne Copin, and Joelle Lepage for excellent technical assistance. This work was supported in part by grants from the Fonds Européen de Développement Régional (FEDER) Conseil Regional Nord-Pas-de Calais (Genopole) to H.M., by National Institutes of Health Grant HL-42630 to N.M., and from the Fondation Leducq to J.C.F.

REFERENCES

1. Miller, N., and A. R. Tall. 1992. High Density Lipoproteins and Atherosclerosis III. Excerpta Medica, Amsterdam.

2. Karathanasis, S. K. 1985. Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CHI, and AIV genes. Proc. Natl. Acad. Sci. USA. 82: 6574–6578.

3. Pennacchio, L. A., M. Oliver, J. A. Hubacek, J. C. Cohen, D. R. Cox, J. C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and by comparable sequencing. Science. 294: 169–173.

4. Sori-Thomas, M., M. M. Prack, N. Dashii, F. Johnson, L. L. Rudel, and D. L. Williams. 1989. Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A1 gene: role of adipose tissue cell proliferation in the regulation of high density lipoproteins. J. Lipid Res. 30: 1397–1403.

5. Rothblat, G. H., F. H. Mahlberg, W. J. Johnson, and M. C. Phillips. 1992. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. J. Lipid Res. 33: 1091–1097.

6. Fielding, C. J., V. G. Shore, and P. E. Fielding. 1972. A proteincofactor of lecithin:cholesterol acyltransferase. Biochem. Biophys. Res. Commun. 46: 1493–1498.

7. Glomset, J. A. 1968. The plasma lecithin:cholesterol acyltransferase reaction. J. Lipid Res. 9: 155–167.

8. Utermann, G., and U. Beisiegel. 1979. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. Eur. J. Biochem. 99: 333–343.

9. Steinmetz, A., R. Barbaras, N. Ghalim, V. Clavey, J. C. Fruchart, and P. Denefle. 1996. Protection against atherosclerosis in mice mediated by human apolipoprotein AIV. Science. 273: 966–968.

10. Ebara, T., R. Ramakrishnan, G. Steiner, and N. S. Shachter. 1997. Chylomicronemia due to apolipoprotein C-III overexpression in apolipoprotein E-null mice. J. Clin. Invest. 99: 2672–2681.

11. Vergnes, L., N. Barouki, M. A. Ostos, G. Castro, N. Duverger, M. N. Nanjee, J. Najib, J. C. Fruchart, N. Miller, M. Zakin, et al. 2000. Expression of human apolipoprotein AI/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20: 2267–2274.

12. Williamson, R., D. Lee, J. Hagaman, and N. Maeda. 1992. Marked reduction of high-density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A1. Proc. Natl. Acad. Sci. USA. 89: 7134–7138.

13. Sambrook, J., T. Maniatis, and E. F. Fritsch. 1989. Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

14. Warnick, G. R., J. Benderson, and J. J. Albers. 1982. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin. Chem. 28: 1379–1388.

15. de la Llera-Moya, M., V. Atger, J. L. Paul, N. Fournier, N. Moatti, P. Giral, K. E. Friday, and G. H. Rothblat. 1994. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: relationships between serum components and efflux, esterification and transfer. Arterioscler. Thromb. 14: 1056–1065.

16. Paigen, B., A. Morrow, P. A. Holmes, D. Mitchell, and R. A. Williams. 1987. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 68: 231–240.

17. Flum, A. S., J. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343–353.

18. Bisgaier, C. L., O. P. Sachdev, L. Megna, and R. M. Glickman. 1985. Distribution of apolipoprotein A1/A4/A5 in human plasma. J. Lipid Res. 26: 11–25.

19. Tall, A. R., P. Costet, and N. Wang. 2002. Regulation and mechanisms of macrophage cholesterol efflux. J. Clin. Invest. 110: 899–904.

20. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468–471.

21. Basu, S. K., J. L. Goldstein, and M. S. Brown. 1983. Independent pathways for secretion of cholesterol and apolipoprotein E by macrophages. Science. 219: 871–875.

22. Linton, M. F., J. B. Atkinson, and S. Fazio. 1995. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267: 1034–1037.

23. Assmann, G. A., von H. J. Biersack, and H. B. Brewer. 1995. Familial HDL deficiency: Tangier disease. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New-York. 2053–2072.

24. Sakai, N., B. L. Vaisman, C. A. Koch, R. F. Hoyt, Jr., S. M. Meyn, G. D. Talley, J. A. Paiz, H. B. Brewer, Jr., and S. Santamarina-Fojo. 1997. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J. Biol. Chem. 272: 7506–7510.

25. Orso, E., C. Brocardo, W. E. Kaminski, A. Bottcher, G. Liebisch, W. Drobnik, A. Gutz, O. Chambenoit, W. Diederich, T. Langmann, et al. 2000. Transport of lipids from Golgi to plasma membrane in defective in Tangier disease patients and Abetalipoproteinemic mouse. Nat. Genet. 24: 192–196.

26. McNeish, J., R. J. Aiello, D. Guyot, T. Turi, C. Gabel, C. Aldinger, K. L. Hoppe, M. L. Roach, L. J. Royer, J. de Wet, et al. 2000. High density lipoprotein deficiency and foam cell accumulation in mice.
with targeted disruption of ATP-binding cassette transporter-1. 
*Proc. Natl. Acad. Sci. USA.* **97:** 4245–4250.

36. Gao, J., Y. Wei, Y. Huang, D. Liu, G. Liu, M. Wu, L. Wu, Q. Zhang, Z. Zhang, R. Zhang, et al. 2005. The expression of intact and mutant human apoAI/CIII/AIV/AV gene cluster in transgenic mice. 
*J. Biol. Chem.* **280:** 12559–12566.

37. Moore, R. E., M. A. Kawashiri, K. Kitajima, A. Secreto, J. S. Millar, D. Pratico, and D. J. Rader. 2003. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. 
*Arterioscler. Thromb. Vasc. Biol.* **23:** 1914–1920.

38. Furbee, J. W., Jr., J. K. Sawyer, and J. S. Parks. 2002. Lecithin: cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knock-out mice. 
*J. Biol. Chem.* **277:** 3511–3519.

39. Aiello, R. J., D. Brees, P. A. Bourassa, L. Royer, S. Lindsey, T. Coskran, M. Haghpasand, and O. L. Francone. 2002. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. 
*Arterioscler. Thromb. Vasc. Biol.* **22:** 630–637.

40. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low density lipoproteins. 
*J. Clin. Invest.* **96:** 2882–2891.

41. Hayek, T., J. Oiknine, G. Dankner, J. G. Brook, and M. Aviram. 1995. HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. 
*Eur. J. Clin. Chem. Clin. Biochem.* **33:** 721–725.

42. Cockerill, G. W., J. Saklatvala, S. H. Ridley, H. Yarwood, N. E. Miller, B. Oral, S. Nithyananthan, G. Taylor, and D. O. Haskard. 1999. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. 
*Arterioscler. Thromb. Vasc. Biol.* **19:** 910–917.